Benzinga | Aug 11, 2020 04:26PM EDT

Sunesis Pharmaceuticals Q2 EPS $(0.06), Inline

Sunesis Pharmaceuticals (NASDAQ:SNSS) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 33.33 percent increase over losses of $(0.09) per share from the same period last year.